| Management of post‐transplant lymphoproliferative disorders CB DeStefano, SH Desai, AG Shenoy, JP Catlett British journal of haematology 182 (3), 330-343, 2018 | 77 | 2018 |
| Heterogeneity in refractory acute myeloid leukemia S Horibata, G Gui, J Lack, CB DeStefano, MM Gottesman, CS Hourigan Proceedings of the National Academy of Sciences 116 (21), 10494-10503, 2019 | 53 | 2019 |
| Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia M Goswami, G Gui, LW Dillon, KE Lindblad, J Thompson, J Valdez, ... Journal for immunotherapy of cancer 10 (1), 2022 | 38 | 2022 |
| Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia H Çelik, KE Lindblad, B Popescu, G Gui, M Goswami, J Valdez, ... Blood Advances 4 (2), 367-379, 2020 | 35 | 2020 |
| CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges MJ Rendo, JJ Joseph, LM Phan, CB DeStefano Blood and lymphatic cancer: targets and therapy, 119-136, 2022 | 29 | 2022 |
| Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis LW Dillon, J Ghannam, C Nosiri, G Gui, M Goswami, KR Calvo, ... Blood cancer discovery 2 (4), 319-325, 2021 | 28 | 2021 |
| Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia KE Lindblad, J Thompson, G Gui, J Valdez, T Worthy, H Tekleab, ... Blood 132 (Supplement 1), 1437-1437, 2018 | 27 | 2018 |
| Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical response HY Wong, AD Sung, KE Lindblad, S Sheela, GW Roloff, D Rizzieri, ... Frontiers in oncology 8, 669, 2019 | 20 | 2019 |
| Treatment of refractory delayed onset heparin‐induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG) K Doucette, CB DeStefano, NA Jain, AL Cruz, V Malkovska, K Fitzpatrick Research and Practice in Thrombosis and Haemostasis 1 (1), 134-137, 2017 | 19 | 2017 |
| Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice CB DeStefano, CS Hourigan Therapeutic advances in hematology 9 (5), 109-121, 2018 | 18 | 2018 |
| DA‐EPOCH‐R for post‐transplant lymphoproliferative disorders CB DeStefano, V Malkovska, H Rafei, A Shenoy, K Fitzpatrick, A Aggarwal, ... European Journal of Haematology 99 (3), 283-285, 2017 | 11 | 2017 |
| The impact of environmental ultraviolet exposure on the clinical course of mycosis fungoides CB DeStefano, S Desale, SJ Fernandez, AG Shenoy Journal of the American Academy of Dermatology 81 (5), 1074-1077, 2019 | 10 | 2019 |
| The evolving AML genomic landscape: therapeutic implications S Horibata, G Alyateem, CB DeStefano, MM Gottesman Current cancer drug targets 20 (7), 532-544, 2020 | 9 | 2020 |
| The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma CB DeStefano, SJ Gibson, AS Sperling, PG Richardson, I Ghobrial, ... Seminars in Oncology 49 (1), 19-26, 2022 | 7 | 2022 |
| Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemia B Popescu, S Sheela, J Thompson, S Grasmeder, T Intrater, ... Clinical hematology international 2 (1), 27-31, 2020 | 6 | 2020 |
| Survival of patients with multiple myeloma diagnosed with second primary malignancies: an ASCO Cancerlinq analysis JD Cooper, JA Thornton, SJ Gibson, K Pham, K Sunderland, ... Blood 140 (Supplement 1), 10039-10040, 2022 | 5 | 2022 |
| Combinatorial immunotherapy and chemotherapy CB DeStefano, SV Liu Early phase cancer immunotherapy, 199-218, 2018 | 4 | 2018 |
| Warfarin management in the setting of FVII deficiency and mechanical circulatory support C DeStefano, K Sylvester, J Connors, F Sheikh, J Catlett Vascular Medicine 22 (4), 345-346, 2017 | 3 | 2017 |
| Current and prospective antibody-based therapies in multiple myeloma E Bryer, C DeStefano, D Kazandjian Seminars in oncology 49 (1), 41-47, 2022 | 2 | 2022 |
| Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or … D Kazandjian, C DeStefano, A Dew, E Hill, K Thoren, O Landgren Blood 142 (Supplement 1), 4770-4770, 2023 | 1 | 2023 |
